Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT, United States



Survival: 8.3 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: New Haven, CT
   
Hospital: Yale Cancer Center and Smilow Cancer Hospital
   
Journal: Link
   
Date: 4/2012

Description:
Patients:
This phase II study involved non-small cell lung cancer patients who had not been previously treated with chemotherapy and were divided into separate treatment groups. Group A consisted of 66 patients with a median age of 62 years and 74% male. Group B consisted of 70 patients with a median age of 59 years and 76% male.

Treatment:
Patients in group A were treated with the chemotherapy agents paclitaxel and carboplatin.

Patients in group B were treated with paclitaxel and carboplatin in addition to the biologic therapy agent ipilimumab, which is a monoclonal antibody that blocks a protein called CTLA-4 and helps the immune system target cancer cells.

Toxicities:
There was one treatment-related death due to sepsis (infection) reported in group A. Grade 4 thrombocytopenia and neutropenia was also reported.

There was one treatment-related death due to sepsis (infection) reported in group B. Grade 4 fatigue, neutropenia, and anemia were also reported.

Results:
The median overall survival for groups A and B were 8.3 and 9.7 months, respectively.

Support:
This study was supported by Bristol-Myers Squibb, makers of ipilimumab (brand name Yervoy).

Correspondence: Dr. Thomas Lynch; email: thomas.lynch@yale.edu

E-mail to a Friend Email Physician More Information